Understanding Ulcerative Colitis and Crohn’s Disease

Understanding Ulcerative Colitis and Crohn’s Disease

Ulcerative colitis (UC) and Crohn’s disease (CD) are two inflammatory bowel diseases that are characterised by chronic inflammation in the gastrointestinal (GI) tract.7,8 Together, they affect an estimated 260,000 people in the UK, typically during early adulthood or between the ages of 55 and 65 years.2,3 While there is no known cure, medical treatments, lifestyle interventions and surgery can greatly reduce symptoms and bring about remission.2 3 7 8

LEARN MORE

What is it Like to Have IBD?

What is it like to have IBD?

Patients with IBD can experience some very awkward and distressing symptoms including abdominal pain, diarrhoea, rectal bleeding, fever, weight loss, signs of malnutrition11.

Learn More

What is Entyvio (vedolizumab)?

What is Entyvio?

Entyvio is the first gut-selective biologic approved for the treatment of adults with moderately to severely active UC or CD who have experienced an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.1

LEARN MORE

The GEMINI™ Studies

The GEMINI Studies

The GEMINI™ Studies5,6,15,16 involved 2,400 individuals with UC or CD who were recruited from nearly 40 countries. GEMINI is the largest phase III clinical trial programme to date that evaluated a new treatment for UC or CD concurrently.

LEARN MORE
About Takeda

About Takeda

Takeda Pharmaceutical Company Limited has a long history in the research and development, manufacturing, sales and marketing, and import/export of pharmaceutical products. The corporate mission to “strive towards better health for people worldwide through leading innovation in medicine” has led to the development of several state-of-the-art medicines, including Entyvio for UC and CD.

LEARN MORE

If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet for Entyvio.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.